- GSK
- 22 October 2025 09:15:02
Source: Sharecast
GSK said its low-carbon version of Ventolin met all primary endpoints in a phase III study, showing non-inferiority in lung function compared to the current Ventolin Evohaler. The new inhaler uses a next-generation propellant with a 90% lower global warming potential, and GSK said it plans to proceed with regulatory submissions, with launch expected from 2026.
Separately, GSK reported positive phase II results for latozinemab, its investigational treatment for frontotemporal dementia linked to progranulin gene mutations.
While the treatment showed "a statistically significant effect" on the biomarker co-primary endpoint of plasma progranulin concentrations, it did not demonstrate a benefit in slowing FTD-GRN progression, the clinical co-primary endpoint. Furthermore, secondary and exploratory endpoints did not show treatment-related effects.
"Based on these results, the open-label extension portion of the INFRONT-3 trial and the continuation study for latozinemab will be discontinued," said GSK.
As of 0915 BST, GSK shares were down 0.33% at 1,640p.
Reporting by Iain Gilbert at Sharecast.com